Meeting Banner
Abstract #3756

Resting-state fMRI fails to detect disease progression in a multicenter randomized clinical trial of Alzheimer's disease

Coimbra Alexandre1, Farshid Faraji1, Alexander de Crespigny1, Lee Honigberg1, Robert Paul1, and David Clayton1

1Research and Early Development, Genentech, South San Francisco, CA, United States

RS-fMRI was implemented in two multicenter clinical trials of a novel therapeutic for AD. Although data of good quality were acquired, none of three functional connectivity metrics (FCMs) showed significant progression associated with disease in placebo-treated patients: changes in connectivity in this mild-to-moderate AD population were less than the measurement precision. Significant cognitive decline and brain atrophy were observed. Test-retest precision was similar to other single-center studies. Operational and acquisition improvements could increase data quality (though difficult in multicenter trials), but more sensitive analysis will be needed for RS-fMRI to be a useful tool for the development of AD therapeutics.

This abstract and the presentation materials are available to members only; a login is required.

Join Here